drugset / Trial / NCT03167177

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

NCT03167177

Phase 1/2 Withdrawn ImmunityBio, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with melanoma who have progressed on or after chemotherapy and anti-PD-1/PD-L1 therapy.

Timeline

Start
2017-12
Primary completion
2019-01
Completion
2021-12-28

Drugs

EvaluationDrugModalityDoseRoute
Background Avelumab Monoclonal antibody
Background Bevacizumab Monoclonal antibody
Background Capecitabine Small molecule
Background Cisplatin Other / unclassified
Background Cyclophosphamide Other / unclassified
Background ETBX-011 Vaccine
Background ETBX-051 Vaccine
Background ETBX-061 Vaccine
Background GI-6207 Vaccine
Background GI-6301 Vaccine
Background Leucovorin Small molecule
Background Lovaza Other / unclassified
Background N-803 Protein / enzyme biologic
Background Nivolumab Monoclonal antibody
Background Paclitaxel Small molecule
Background fluorouracil Small molecule
Background haNK Cell therapy

Indications